Michael R Hayden, Director at AbCellera Biologics, bought ABCL on Aug 12, 2026

Data as of Oct 16

▲ BUY$481K46,387 shares at $10.37Michael R Hayden DirectorABCL AbCellera Biologics Inc.

Watch ABCL

Traded: Aug 12, 2026
Disclosed: Aug 14, 2026
Filed: 2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

ABCLSimilar stocks (XLV — its sector index fund), rebased to ABCL's price on the disclosure day

ABCL since disclosure

+3.7%

Similar stocks (XLV) since disclosure

+5.6%

XLV — its sector index fund

Change in closing price from Aug 14, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

⚪ CFO buys $25K+ of own stock — fired on this disclosure day
Not enough evidence · In past tests: 3.6 percentage points better than similar stocks over 3 months · 2,178 tries
⚪ CFO buys $25K+ of own liquid stock — fired on this disclosure day
Not enough evidence · In past tests: 2.0 percentage points better than similar stocks over 3 months · 1,426 tries

What this rule is doing with ABCL right now

See pricing →

Already a member? Sign in

See every trade on ABCL →